In this episode, we are joined by Drs. Mamta Agarwal and Miel Sundararajan to discuss the medical and surgical approaches to managing infectious scleritis.

The discussants report no relevant financial disclosures.

In this episode, we summarize several key clinical research papers from 2024.

The discussants report no relevant financial disclosures.

In the second part of this two-part series, we continue our discussion with Drs. Eric Suhler and George Mount regarding the use of biologics for the management of non-infectious uveitis.

Disclosures:
Dr. Suhler has consulted for Abbvie

In the first part of this two-part series, we are joined by Drs. Eric Suhler and George Mount to discuss the use of biologics for the management of non-infectious uveitis.

Disclosures:
Dr. Suhler has consulted for Abbvie

In this episode, we are joined by uveitis specialist, Dr. Lyndell Lim and maternal-fetal medicine specialist, Dr. Kelly Kuo to discuss management of uveitis in pregnant patients.

The discussants report no relevant financial disclosures.

In this episode, we are joined by pulmonologist, Dr. Amy Malik and uveitis specialist, Dr. Ananth Sastry to discuss the ocular and systemic considerations in sarcoidosis.

The discussant report no relevant financial disclosures.

In this episode, we are joined by Drs. Lucia Sobrin and Tim Boyce to discuss the perplexing condition that is autoimmune retinopathy.

The discussants report no relevant financial disclosures.

In this episode, we are joined by Drs. Meghan Berkenstock and Meredith McKean to discuss uveitis secondary to immune checkpoint inhibtor use.

In this episode, we are joined by Drs. John Kempen and Sapna Gangaputra to review the many ways the SITE cohort study has shaped the way we approach uveitis.

Drs. Kempen and Gangaputra have received grant support from the NIH for their work on the SITE cohort study.

In this episode we are joined by Drs. Debra Goldstein and Mark Dacey to discuss the manifestations, treatment approach and special considerations for ocular syphilis.

The discussants report no relevant financial disclosures.